

Alma Mater Studiorum Università di Bologna
Archivio istituzionale della ricerca

High-Risk Pregnancy Is Associated With Increased Alpha-Fetoprotein Concentrations in the Amniotic Fluid and Foal Plasma

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

High-Risk Pregnancy Is Associated With Increased Alpha-Fetoprotein Concentrations in the Amniotic Fluid and Foal Plasma / Lanci, Aliai; Mariella, Jole; Ellero, Nicola; Canisso, Igor F; Dondi, Francesco; Castagnetti, Carolina. - In: JOURNAL OF EQUINE VETERINARY SCIENCE. - ISSN 0737-0806. - ELETTRONICO. - 119:(2022), pp. 104124.1-104124.9. [10.1016/j.jevs.2022.104124]

Availability:

This version is available at: <https://hdl.handle.net/11585/904837> since: 2022-11-21

Published:

DOI: <http://doi.org/10.1016/j.jevs.2022.104124>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).
When citing, please refer to the published version.

(Article begins on next page)

This is the final peer-reviewed accepted manuscript of:

High-Risk Pregnancy Is Associated with Increased Alpha-Fetoprotein Concentrations in the Amniotic Fluid and Foal Plasma, Journal of Equine Veterinary Science, Volume 119, 2022, 104124,

The final published version is available online at:

<https://doi.org/10.1016/j.jevs.2022.104124>.

Rights / License:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>)

When citing, please refer to the published version.

1 Original Research

2 **Title. High-risk pregnancy is associated with increased alpha-fetoprotein concentrations in**
3 **the amniotic fluid and foal plasma**

4 Aliai Lanci^a, Jole Mariella^{a*}, Nicola Ellero^a, Igor F. Canisso^c, Francesco Dondi^a and Carolina
5 Castagnetti^{a,b}

6 a Department of Veterinary Medical Sciences, University of Bologna, Via Tolara di Sora 50,
7 Ozzano dell'Emilia, 40064 Bologna, Italy.

8 b Health Science and Technologies Interdepartmental Center for Industrial Research (HST-
9 ICIR), University of Bologna, Via Tolara di Sopra 41/E, Ozzano dell'Emilia, 40064 Bologna, Italy

10 c Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of
11 Illinois Urbana-Champaign, Urbana IL 61802.

12 * Corresponding author: jole.mariella2@unibo.it; Department of Veterinary Medical Sciences,
13 University of Bologna, Via Tolara di Sora 50, Ozzano dell'Emilia, 40064 Bologna, Italy.

14

15

16

17

18

19

20

21

22

23

24

25

26 **Abstract**

27 This study aimed to determine alpha-fetoprotein (AFP) concentrations in amniotic fluid, plasma of
28 mares and respective foals: carrying normal pregnancies and delivering healthy foals (n=20; Group
29 1); carrying apparently normal pregnancies and delivering sick foals (n=15; Group 2); carrying high-
30 risk pregnancies and delivering sick foals (n=14; Group 3). High-risk pregnancy was defined by a
31 history of premature udder development/lactation or increased of the combined thickness of the uterus
32 and placenta, or vulvar discharge and/or mares' systemic illness. Sick foals were affected by neonatal
33 encephalopathy, sepsis, prematurity/dysmaturity, or hypoxic-ischemic encephalopathy. Based on
34 histological examination of the chorioallantois, AFP trend was analyzed in pregnancies with
35 **pathologic** (PFM) and normal fetal membranes (NFM). Concentrations of AFP were measured using
36 a commercially available immunoassay previously validated for horses. Mares' plasma AFP did not
37 change during the last 15-20 days of pregnancy in the three groups, and there was no difference
38 among them. Amniotic fluid AFP was higher in Group 3 ($p=0.014$). **Foals' plasma AFP** concentration
39 was higher from birth to 72h in foals of Group 2 and 3 than in healthy ones, and foals of Group 3 had
40 the highest value. The strong association ($r=0.84$; $p<0.0001$) between AFP in amniotic fluid and foals'
41 plasma at birth is likely due to the presence of AFP in fetal urine. AFP was higher in pregnancy with
42 PFM than with NFM in mare's plasma at admission ($p=0.031$), amniotic fluid ($p=0.004$), foal's
43 plasma at birth ($p=0.002$), at 24 ($p=0.005$) and at 72 hours of life ($p=0.004$). AFP is higher in
44 pregnancy with histopathological lesions of the chorioallantois providing the evidence of the
45 differences between pregnancy with a normal placental barrier and the more compromised ones. The
46 increased AFP concentration in the amniotic fluid and plasma of high-risk foals suggests
47 upregulation.

48
49 **Keywords:** Alpha-fetoprotein; mare; neonatal foal; amniotic fluid; high-risk pregnancy

50

51

52

53 **1. Introduction**

54 Alpha-fetoprotein (AFP) is a glycoprotein first discovered in human fetuses in 1956, and then its
55 presence and the putative role was significantly expanded in the following decades across mammalian
56 species [1]. Early in pregnancy, AFP is produced by the yolk sac, and then the fetal liver and
57 gastrointestinal tract system take over AFP production after regression of the yolk sac [2].

58 AFP is a member of the albuminoid superfamily associated with estrogen binding, heavy metals, and
59 immuno-modulation [3-5]. During human pregnancy, AFP begins to rise from the end of the first
60 trimester, peaks during the second trimester, and then begins to fall after 32 weeks of gestation [6].
61 In women, AFP concentrations have high predictive values for preterm placenta-mediated adverse
62 pregnancy outcomes [7]. In addition, high AFP levels are associated with multiple pregnancies,
63 pathologic conditions such as neural tube defects [8], abortion [9], congenital nephrosis [10],
64 intrauterine growth retardation [11], preeclampsia [12], and preterm birth in the asymptomatic woman
65 [13].

66 In horses, AFP was first described in the plasma of early pregnant mares [14]. The same study also
67 reported that twin pregnancies have greater AFP concentrations than singleton pregnancies [14]. Of
68 interest, concentrations of AFP were increased in plasma of mares experiencing pregnancy loss [14].
69 Thereafter, AFP was demonstrated to be present in high concentrations in the fetal fluids of pregnant
70 mares and to be increased in plasma of mares with experimentally induced placentitis when compared
71 to gestationally age-matched healthy mares [15]. Subsequently, AFP was investigated throughout
72 pregnancy in Lipizzaner mares carrying normal pregnancies [16]. Thereafter, a study demonstrated
73 that AFP is present in the plasma of foals in high concentrations, and there was a decline in the first
74 week of life [17]; the same study determined that healthy Thoroughbred foals have lower
75 concentrations than foals becoming sick during the first week of life [17].

76 This study aimed to evaluate the AFP concentration in mares' plasma, amniotic fluid, and foal plasma
77 in both normal and high-risk pregnancy to understand if AFP could be used as a marker of high-risk

78 pregnancy in field condition. We hypothesized AFP is higher in mares with a high- risk pregnancy,
79 particularly in mares with placenta-mediated adverse pregnancy outcome, as described in women [7]
80 and that these higher concentrations are the reflection of the high concentration in their respective
81 foal and amniotic fluid.

82

83 **2. Materials and Methods**

84 **2.1 Animals**

85 The study was carried out as a prospective observational study with client-owned mares presented for
86 foaling management to the Equine Perinatology and Reproduction Unit of the Department of
87 Veterinary Medical Sciences of the University of Bologna during the 2018 and 2019 foaling seasons.
88 Mare's breed, age and parity were recorded.

89 The mares were divided into three groups: mares carrying normal pregnancies and delivering healthy
90 foals (Group 1); mares carrying apparently normal pregnancies and delivering sick foals (Group 2);
91 and mares carrying high-risk pregnancies and delivering sick foals (Group 3). High-risk pregnancy
92 was defined as a history of premature udder development/lactation, increase of the combined
93 thickness of the uterus and placenta, vulvar discharge, and/or mare's systemic illness. Mares with
94 dystocic delivery due to fetal or maternal causes were excluded from the study.

95 The mares were admitted due to apparent clinical problems (n= 14), or owners' concern for unattended
96 foaling (n= 33), or history of clinical problems in the previous pregnancies (n= 2). All mares were
97 admitted approximately by 310 days of gestation and remained on around-the-clock observation until
98 at least 7 days postpartum. The mares were kept in stalls (4 x 4 m) and fed hay ad libitum and
99 concentrate twice a day. All the mares received a complete physical examination twice a day during
100 the hospitalization and a complete blood cell count and blood chemistry at admission. Additionally,
101 transrectal palpation and ultrasonographic examination were performed to evaluate the combined
102 thickness of the uterus and placenta (CTUP) at admission and every ten days until parturition. The
103 reference ranges of CTUP were considered related to gestational age, as reported elsewhere [18,19].

104 The time from admission to foaling were recorded as Days Before Parturition (DBP). After
105 parturition, the foals were classified as healthy when they had a normal clinical evaluation during
106 hospitalization, including a complete blood count and serum biochemistry at birth and an IgG serum
107 concentration \geq of 800 mg/dL at 24 h of life [20]. Foals affected by Hypoxic-Ischemic
108 Encephalopathy (HIE) with evidence of dystocic parturition were excluded. Foals with the same
109 clinical presentation but without evidence of a hypoxic insult were classified as affected by Neonatal
110 Syndrome (NS) [24]. Foals were defined as premature when born prior to 320 days of gestation and
111 dysmature when born after 320 days both with immature physical characteristics: low body weight
112 or small for gestational age respectively, inability to maintain body homeostasis and to suckle,
113 hyperextension of flexor tendons in the, or both, incomplete carpal and tarsal bone ossification.
114 Laboratory findings in premature foals can show a narrower neutrophil-lymphocyte ratio than in
115 healthy term foal, with a higher lymphocyte count [25]. Foals were classified as septic in the presence
116 of both infections, confirmed based on positive blood culture, culture of pathogens from local sites
117 of suspected infection, or based on postmortem examination, and systemic inflammatory response
118 [26].

119 Fetal membranes were grossly evaluated immediately after delivery. For histological evaluation,
120 samples were collected, fixed in formalin, and then embedded in paraffin and routine histological
121 hematoxylin-eosin (HE) stained slides were obtained. Diagnosis of placental insufficiency was
122 performed retrospectively after macroscopic and histopathologic examination of the placenta [21-23].
123 Based on chorioallantois histological exam results and independently from the type of pregnancy,
124 mares were also divided into 2 Groups: pathologic fetal membranes Group (PFM Group) and normal
125 fetal membranes Group (NFM Group).

126 2.2. Samples collection and analysis

127 All samples were harvested as part of the clinical program of peripartum monitoring; owners gave
128 consent to use samples for research. All blood samples were collected by jugular venipuncture into
129 plastic tubes containing anticoagulant for routine CBC and biochemistry analysis. For the study

130 purpose an aliquot of plasma sample for each subject was centrifuged at 600 g/10 min within 30
131 minutes of collection, stored at -20°C, and then analyzed at the end of each foaling season. Mares'
132 plasma was collected at admission, then every ten days, and at foaling. Amniotic fluid was collected
133 by direct puncture of the amniotic membrane after its projection through the vulva. Foals' plasma was
134 collected soon after delivery (T0), at 24 (T24) and 72 (T72) hours after birth. Concentrations of AFP
135 were determined using a heterologous commercially available immunoassay on a chemiluminescence
136 platform (Immulite® 2000, Siemens), previously validated for horses as described elsewhere [15].
137 The AFP assay has a range of 0.2 to 300 units/mL. The samples above the upper detection limit were
138 diluted with the diluent of the commercial kit. According to the manufacturer, a conversion factor of
139 1.21 was applied for conversion of IU/mL to ng/mL of human AFP.

140

141 2.3. Statistical analysis

142 The Kolmogorov–Smirnov test was used to assess data for normal Gaussian distribution. Since data
143 were non-normally distributed, they were assessed with non-parametric tests. Correlations of AFP
144 concentrations between mare plasma, foal plasma, and amniotic fluid were assessed with Spearman's
145 correlation test. Differences among sampling times were assessed with Kruskal-Wallis test followed
146 by post-hoc analysis. Differences between males and females in foal's plasma AFP concentration at
147 birth were assessed with the Mann-Whitney test. Differences between the group NFM and PFM were
148 assessed with the Mann-Whitney-U-test.

149 Spearman's correlation test was used to assess the associations of AFP concentrations (amniotic fluid,
150 mare, and foal plasma), gestational length, foals' weight, and complete blood count and blood
151 chemistry parameters at birth. Data were presented as median and interquartile ranges. Significance
152 was set as $P < 0.05$. All the data analysis was performed with a statistic software (SPSS).

153

154 3. Results

Forty-nine mares were included in the study. Twenty mares were included in Group 1 (normal pregnancy and healthy foal), 15 mares in Group 2 (apparently normal pregnancy and sick foal), and 14 mares in Group 3 (high-risk pregnancy and sick foal) (Table 1). Foals in Group 2 had neonatal encephalopathy (n= 11) and HIE (n= 4), defined as described elsewhere [24]. Mares included in Group 3, presented: premature udder development and increased CTUP (n= 11), laminitis (n= 1), colic surgery at 282 d of gestation (n= 1), and prepubic tendon rupture with severe ventral abdominal hernia (n= 1). Foals born from these mares had a variety of clinical diagnosis: prematurity/dysmaturity (n= 4) and sepsis (n= 2), neonatal encephalopathy (n= 3) and HIE (n= 3). Two foals were stillborn. Mares suffering from dystocia and their foals were excluded from the study. Foal complete blood cell count and chemistry parameters at birth are depicted below (Table 2 and 3). Foals in Group 3 had lower hemoglobin (p=0.0222), erythrocyte (p=0.0071), lymphocyte (p=0.0072), and monocyte (p=0.0284) count in comparison with foals in the other two groups. On the other hand, ionized calcium (p=0.0065) was greater in foals of Group 3 than in the others. In Group 1, all fetal membranes were grossly normal. Four out of 15 fetal membranes in Group 2 and 12 out of 13 in Group 3 presented a variety of abnormalities. Fetal membranes in Group 2 presented chorionic villi hypoplasia (n=4); in Group 3, fetal membranes presented chorionic villi hypoplasia (n= 2), severe edema (n= 7), thickness of the chorioallantois with exudate, necrotic and avillous area (n= 3). In Group 3, one fetal membrane was not evaluated as the mare was euthanized before placenta expulsion due to prepubic tendon rupture and severe ventral abdominal hernia. The gross and histopathological findings of the chorioallantois in three representative subjects of the Groups 2 and 3 were described in Fig.1. Data about mare and pregnancy of Group 1, Group 2 and Group 3 are illustrated in Table 3, 4 and 5, respectively. The average of DBP was 19 ± 3 days in Group 1, 20 ± 9 days in Group 2, and 19 ± 10 in Group 3.

Data about AFP concentration in mares' plasma, amniotic fluid and foals' plasma are reported in Table 6. Mares' plasma AFP did not change from admission to foaling in the three Groups. There were no statistical differences between males and females in foal's plasma AFP concentration at birth.

181 In Group 1, Spearman correlation test found a significant correlation between AFP concentration in
182 amniotic fluid and in foals' plasma at birth ($r=0.76$; $p<0.001$), in foals' plasma at 24h ($r=0.78$;
183 $p<0.001$) and in foal's plasma at 72h ($r=0.79$; $p<0.001$). In Group 2, Spearman correlation test found
184 a significant correlation between foals' plasma AFP at birth and foals' plasma AFP at 24h ($r=0.82$,
185 $p<0.01$). In all the three Groups, AFP concentrations followed the same pattern during the first 72
186 hours of life with the highest concentration at birth and the decline over 72 h. In Group 1, foals'
187 plasma concentrations of AFP were different among the three different sampling times ($p<0.001$). In
188 Group 2, AFP concentration followed the same pattern, and a significant difference was found
189 between foals' plasma AFP at birth and after 24 hours ($p<0.001$), between foals' plasma AFP at 24h
190 and at 72h ($p<0.05$), between foals' plasma AFP at birth and at 72 h ($p<0.01$). In Group 3, a significant
191 difference was found between foals' plasma AFP at birth and after 24 hours ($p<0.001$), between foals'
192 plasma AFP at 24h and at 72h ($p<0.05$), between foals' plasma AFP at birth and at 72 h ($p<0.001$).
193 In Group 3, Spearman correlation test found a significant correlation between foals' plasma AFP at
194 birth and at 24h ($r=0.83$, $p=0.003$). The analysis of differences among Groups found a significant
195 difference among AFP concentration in amniotic fluid ($p=0.014$), in particular the post-hoc analysis
196 revealed differences of both Group 1 ($p=0.04$) and Group 2 ($p=0.027$) with Group 3. A similar trend
197 was found among the AFP concentrations in foals' plasma at birth ($p<0.001$) and in particular the
198 post-hoc analysis revealed differences of both Group 1 ($p<0.001$) and Group 2 ($p=0.005$) with Group
199 3. Also, the foals' plasma AFP at 24h and 72h were different among the three groups ($p=0.002$) with
200 the same trend between Group 1 ($p<0.001$) and Group 2 ($p=0.023$) with Group 3 at 24h of life; at 72
201 h Group 1 ($p<0.001$) and Group 2 ($p=0.004$) were different from Group 3.

202 At birth, AFP concentration in sick foals' plasma of Group 2 and 3 was positively correlated to
203 lymphocytes counts ($p=0.0275$, $r=0.45$) and negatively correlated with erythrocytes counts ($p=$
204 0.0092 , $r=-0.52$), total bilirubin ($p=0.0405$, $r=-0.43$), and albumin ($p=0.0069$, $r=-0.55$)
205 concentrations. Moreover, AFP concentration at birth in sick foals was negatively associated with
206 foal birthweight ($p=0.0019$, $r=-0.63$) and gestational length ($p=0.0139$, $r=-0.50$).

207 On the basis of histological findings, 31 mares were included in group NFM and 14 in group PFM.
208 Data were showed in Table 8. Unfortunately, for few mares with placental macroscopic alterations,
209 the histological findings were not available, and were not included in the statistical analysis. The
210 Mann-Whitney-U-test found a significant difference as regard AFP concentration in mares' plasma
211 at admission ($p=0.031$), but not at foaling, between the NFM and PFM group, with a higher
212 concentration in the latter. The AFP concentration in amniotic fluid ($p=0.004$) and in foals' plasma
213 at birth ($p=0.002$), at 24 h ($p=0.005$) and at 72 h of life ($p=0.004$) was higher in PFM group than in
214 NFM group.

215

216 4. Discussion

217 The present study was conducted to determine AFP's usefulness as a biomarker in normal and high-
218 risk pregnancies and in their respective neonatal foals. This is the first study to document that AFP is
219 increased in plasma of foals born from high-risk pregnancies. Mares at term have low plasma AFP
220 concentrations. This finding is consistent with two other studies [15,27]. Concentrations of AFP did
221 not change in plasma of mares with high-risk pregnancies herein. A previous study demonstrated that
222 AFP increased in plasma of mares with experimentally induced ascending placentitis [15,28] and
223 another field study demonstrated that AFP increased in plasma of mares with ascending and focal
224 mucoid placentitis [29]. The lack of change in AFP concentration in the present study could be due
225 to an heterogenous population of mares included or because the plasma sampling was too spread out,
226 not allowing us to detect differences between groups. It is possible that if more frequent sampling
227 were used, we could have observed differences. In addition, it is possible that placentitis may alter
228 AFP concentrations more profoundly than other high-risk conditions [29]. The hypothesis of the
229 present study that AFP is higher in mares with high- risk pregnancies has not been confirmed. In the
230 14 mares with a high-risk pregnancy, AFP's mean value was similar to those found in mares with
231 normal pregnancy. However, our sampling herein was too infrequent, so it is possible that we could
232 have missed critical changes in AFP concentrations. As proposed in humans, the fetal membranes are

not a site of AFP production, but when they are compromised, a greater amount of AFP gets transferred from the fetoplacental unit to the maternal circulation [7-8]. Although an increase in AFP concentrations has been documented in mares with placentitis [15,28], this is of much lower magnitude than in human compromised pregnancy, probably due to the differences in the type of placentation between the two species. Primates have hemochorial placentation, which facilitates the exchanges of molecules between the fetoplacental unit and maternal systemic circulation; conversely, mares have epitheliochorial placentation, which makes the exchange of molecules more limited. It is worth noting that in the present study, comparing AFP in mares grouped on the basis of the histological examination of chorioallantois, the difference between pregnancies with normal and compromised placental barrier became more evident, with mares presenting the more severe placenta changes having the greatest AFP plasma values. A study about human term placenta demonstrated that the expression pattern of AFP and its receptor is indicative of a transport of AFP from the fetal into the maternal circulation across the fetal vessel endothelium, the vessel muscle wall, the villous stroma and the syncytiotrophoblast [30]. The presence of AFP receptor has never been investigated in equine chorionic villi, but it can be assumed that a similar transport may also be present in this species and that every condition which alters the placental barrier may increase the concentration of AFP in maternal plasma. It is worth noting that AFP in human medicine is included in a list of maternal circulating biomarkers which reflect placental insufficiency and predict fetal growth restriction [31]. In equine medicine, several factors contribute to placental insufficiency such as premature placental separation, placental villous hypoplasia, placental thickening and especially placentitis. The result of this condition is inadequate fetal nutrition resulting in intrauterine growth retardation, premature delivery or abortion [21-23]. Since in the present study not every mare with pathological histological findings was affected by placentitis, it is possible that the higher concentration of AFP in mare's circulation was related to other causes of placental insufficiency which implies an altered utero-placental blood perfusion and impaired materno-fetal exchange of nutrient, gases and waste products.

259 Immunoassays have been primarily used to measure AFP in horses, an early used immunosorbent
260 enzyme-linked assay to determine AFP concentrations in serum of pregnant mares [14]. More
261 recently, AFP was measured in equine plasma using a heterologous chemiluminescence assay using
262 a platform (Immulite 1000) and kit widely available throughout the world [15,28]. Another study has
263 also used a human immunosorbent enzyme-linked assay to horse pregnancy [16]. The
264 chemiluminescence assay appears to have a more direct application to clinical practice as the results
265 being readily available, and the platform has highly standardized quality control. Thus, the latter assay
266 was used herein to assess AFP concentrations.

267 In farm animals such as cattle, pigs, and sheep, AFP is primarily produced by the fetal liver and
268 secondarily in low levels by the gastrointestinal tract [32-34]; thus, AFP production in horses occurs
269 in these sites. It is possible that high-risk pregnancy resulted in AFP upregulation in the liver and/or
270 gastrointestinal tract of equine fetus. The peripheral increase in AFP observed in mares with
271 experimentally induced placentitis is either due to upregulation by the fetal liver or leakage of this
272 protein in the mares' plasma [15,28]. The increased AFP concentration in the amniotic fluid and
273 plasma of high-risk foals suggests upregulation.

274 It is thought that the presence of AFP in fetal fluids is related to its secretion in the fetal urine, as
275 suggested in humans and in cows [32,35]. It seems possible that AFP enters both amniotic and
276 allantoic fluid as a component of fetal urine since other plasma proteins of similar molecular weight
277 do not appear to cross fetal membranes [35]. In mares, during the third trimester of normal pregnancy,
278 AFP is present in amniotic fluid at a greater concentration than during parturition, as reported
279 elsewhere [15] and by the present study.

280 Concentrations of AFP are detected in mare's plasma from mid to late gestation, although 100-1000-
281 fold lower than in fetus, fetal fluids and newborn foal [15]. On the contrary, newborn foals' plasma
282 had a high concentration of AFP, as happening in the newborn of other species [34,36-37]. Alpha-
283 fetoprotein decreased 72 h after birth as previously reported for other species [32,33], but

284 concentration remained remarkably greater than in adults. In the human newborn, AFP half-life is
285 approximately five days after birth [36]; in the equine neonate, AFP half-life has not been determined.
286 As in other species, AFP in the amniotic fluid of high-risk pregnancy was higher than in healthy
287 pregnancy, and this is probably due to the higher concentrations in the fetal circulation [32,33]. Both
288 **healthy and** sick foals had a reduction in AFP concentrations leading to 72 h after birth, though sick
289 foals still had greater concentrations. A similar trend was reported in a recent study in septic foals
290 born from mares with experimentally induced ascending placentitis [39]. Septic foals had greater AFP
291 concentrations than healthy foals. It has been suggested that AFP behaves as a positive acute-phase
292 protein in the fetus [40].

293 The weak but significant associations between AFP concentrations and lymphocytes, erythrocytes,
294 bilirubin, and albumin could suggest a response to intrauterine inflammation, as proposed in humans
295 [41]. Alpha-fetoprotein is also negatively associated with erythrocyte count in human fetuses [41].
296 The negative correlation with albumin is not surprising since albumin is considered a negative acute-
297 phase protein, and its production by the liver is down-regulated by positive acute-phase proteins, such
298 as AFP [42]. The intrauterine inflammatory environment could be responsible for the lower values of
299 hemoglobin concentration and erythrocyte, lymphocyte, and monocyte number in foals born from
300 high-risk pregnancies [43]. In addition, the negative correlation between AFP and total bilirubin could
301 be since the latter may function as a carrier [44]. The negative correlation between foal's plasma AFP
302 at birth and foal's birth weight and gestational length concurs with that reported in humans, where
303 high values of AFP are found in low-birth-weight newborns and preterm birth babies [38]. Despite
304 the weakness of the correlations obtained in the present study could be a limitation and could result
305 in speculative conclusions, blood parameters need to be critically evaluated with a larger and more
306 homogeneous population, particularly for high-risk pregnancies. This could clarify the clinical role
307 of AFP in equine perinatal period. A previous study suggested that AFP can be a useful screening
308 tool for newborn foals needing further care in the first week of life [17]. As suggested, this could be

309 added in the biomarkers panel of the transitioning phase between intrauterine and extrauterine life in
310 foals [15,28].

311

312 **5. Conclusions**

313 In conclusion, in the studied population of high-risk mares the lack of change in AFP plasma
314 concentration could be due to several conditions presented, ranging from severe placentitis to
315 systemic illness. On the other hand, it is evident that AFP is higher in chorioallantois alterations. The
316 role of AFP and the pathogenesis of its increase in plasma concentration remain to be clarified in
317 newborn foals needing further care.

318

319 **References**

- 320 1. Bergstrand CG, Czar B. Demonstration of a new protein fraction in serum from the human
321 fetus. Scand J Clin Lab Invest 1956;8:174–9.
- 322 2. Gitlin D, Perricelli A, Gitlin GM. Synthesis of alpha-fetoprotein by liver, yolk sac, and
323 gastrointestinal tract of the human conceptus. Cancer Res 1972;32:979-82.
- 324 3. Keel BA, Abney TO. The kinetics of estrogen binding to rat alpha-fetoprotein. Experientia
325 1984;40:503-5.
- 326 4. Peck AB, Murgita RA, Wigzell H. Cellular and genetic restrictions in the immunoregulatory
327 activity of alpha-fetoprotein. III. Role of the MLC-stimulating cell population in alpha-fetoprotein-
328 induced suppression of T cell-mediated cytotoxicity. J Immunol 1982;128:1134-40.
- 329 5. Pressman EK, Thornburg LL, Glantz JC, Earhart A, Wall PD, Ashraf M, et al. Inflammatory
330 cytokines and antioxidants in midtrimester amniotic fluid: correlation with pregnancy outcome. Am
331 J Obstet Gynecol 2001;204:155, e1-7.
- 332 6. Gupta PP, Srivastava RK, Gupta S, Gupta K. Radial immuno diffusion estimation of maternal
333 serum alpha fetoprotein in normal pregnancy and pregnancy-induced hypertension. Indian J Physiol
334 Pharmacol 1987; 31: 273-8.

- 335 7. Tancredi S, Bujold E, Giguère Y, Renald MH, Girouard J, Forest JC. Mid-trimester maternal
336 serum AFP and hCG as markers of preterm and term adverse pregnancy outcomes. *J Obstet Gynaecol*
337 *Can* 2015; 37:111-6.
- 338 8. Macri JN, Anderson RW, Krantz DA, Larsen JW, Buchanan PD. Prenatal maternal dried
339 blood screening with alpha-fetoprotein and free beta-human chorionic gonadotropin for open neural
340 tube defect and Down syndrome. *Am J Obstet Gynecol* 1996;174:566-72.
- 341 9. Mor A, Tal R, Haberman S, Kalgi B, Nasab SH, Minkoff H. Same-day confirmation of
342 intrauterine pregnancy failure in women with first- and early second-trimester bleeding. *Fertil Steril*
343 2018;109:1060-4.
- 344 10. Heinonen S, Ryyänänen M, Kirkinen P, Saarikoski S. Endometrial and fetoplacental markers
345 in pregnancies with fetal congenital nephrosis. *Acta Obstet Gynecol Scand* 1996;75:526-30.
- 346 11. Roig MD, Sabrià J, Valls C, Borràs M, Miró E, Ponce J, Vicens JM. The use of biochemical
347 markers in prenatal diagnosis of intrauterine growth retardation: insulin-like growth factor I, Leptin,
348 and alpha-fetoprotein. *Eur J Obstet Gynecol Reprod Biol* 2005;120:27-32.
- 349 12. Bredaki FE, Matalliotakis M, Wright A, Wright D, Nicolaides KH. Maternal serum alpha-
350 fetoprotein at 12, 22- and 32-weeks' gestation in screening for preeclampsia. *Ultrasound Obstet*
351 *Gynecol* 2016;47:466-71.
- 352 13. Moawad AH, Goldenberg RL, Mercer B, Meis PJ, Iams JD, Das A, et al. The Preterm
353 Prediction Study: the value of serum alkaline phosphatase, α -fetoprotein, plasma corticotropin-
354 releasing hormone, and other serum markers for the prediction of spontaneous preterm birth. *Am J*
355 *Obstet Gynecol* 2002;186:990-6.
- 356 14. Sorensen K, Neely DP, Read W, Grappell PM. Measurement and clinical significance of
357 equine fetal protein in pregnant mares serum. *J Equine Vet Sci* 1990;10:417-21.
- 358 15. Canisso IF, Ball BA, Scoggin KE, Squires EL, Williams NM, Troedsson MH. Alpha-
359 fetoprotein is present in the fetal fluids and is increased in plasma of mares with experimentally
360 induced ascending placentitis. *Anim Reprod Sci* 2015;154:48-55.

- 361 16. Vincze B, Gáspárdy A, Kulcsár M, Baska F, Bálint Á, Hegedűs GT, Szenci O. Equine alpha-
362 fetoprotein levels in Lipizzaner mares with normal pregnancies and with pregnancy loss.
363 Theriogenology 2015;84:1581-86.
- 364 17. Prell M, Canisso IF, Schnobrich MR, Riddle T, Ellerbrock RE. Alpha-fetoprotein as a marker
365 for equine neonatal disease. Proceedings of the Theriogenology Annual Conference, Asheville, USA,
366 27th July;2016.
- 367 18. Renaudin CD, Troedsson MH, Gillis CL, King VL, Bodena A. Ultrasonographic evaluation
368 of the equine placenta by transrectal and transabdominal approach in the normal pregnant mare.
369 Theriogenology 1997;47:559-73.
- 370 19. Bucca S, Fogarty U, Collins A, Small V. Assessment of fetoplacental well-being in the mare
371 from midgestation to term: transrectal and transabdominal ultrasonographic features. Theriogenology
372 2005;64:542-57.
- 373 20. Vaala WE. Perinatology. In: Higgins AJ, Snyder JR, editors. The Equine Manual, 2nd
374 Ed.;W.B. Saunders: London, UK, 2006; p. 803-4.
- 375 21. Laugier C, Foucher N, Sevin C, Leon A, Tapprest J. A 24-year retrospective study of equine
376 abortion in Normandy (France). J Equine Vet Sci 2011;31:116–23.
- 377 22. Vaala WE, Sertich PL. Management strategies for mares at risk for periparturient
378 complications. Vet Clin N Am-Equine 1994;10:237–65.
- 379 23. Ellero N, Lanci A, Ferlizza, E, Andreani G, Mariella J, Isani G, Castagnetti C. Activities of
380 matrix metalloproteinase-2 and-9 in amniotic fluid at parturition in mares with normal and high-risk
381 pregnancy. Theriogenology 2021;172:116-22.
- 382 24. Toribio RE. Equine Neonatal Encephalopathy: Facts, Evidence, and Opinions. Vet Clin North
383 Am Equine Pract 2019;35:363-78.
- 384 25. Knottenbelt DC, Holdstock N, Madigan JE. Equine Neonatology Medicine and surgery.
385 Saunders; 2004; p. 155-363.

- 386 26. Castagnetti C, Pirrone A, Mariella J, Mari G. Venous blood lactate evaluation in equine neonatal
387 intensive care. *Theriogenology* 2010;73:343-57.
- 388 27. Bucca S, De Oliveira IRS, Cunanan JC, Vinardell T, Troedsson MHT. Doppler indices of the
389 equine fetal carotid artery throughout gestation. *Theriogenology* 2020;156:196-204.
- 390 28. Canisso IF, Loux SC, Lima FS. Biomarkers for placental disease in mares. *Theriogenology*
391 2020;150:302-7.
- 392 29. Fedorka CE, Ball BA, Wynn MAA, McCormick ME, Scoggin KE, Esteller-Vico A, et al.
393 Alterations of Circulating Biomarkers During Late Term Pregnancy Complications in the Horse Part
394 II: Steroid Hormones and alpha-fetoprotein. *J Equine Vet Sci* 2021, 99, 103395.
- 395 30. Newby D, Dalgliesh G, Lyall F, Aitken DA. Alphafetoprotein and alphafetoprotein receptor
396 expression in the normal human placenta at term. *Placenta*. 2005; 26(2-3):190-200.
- 397 31. Gaccioli F, Aye ILMH, Sovio U, Charnock-Jones DS, Smith GCS. Screening for fetal growth
398 restriction using fetal biometry combined with maternal biomarkers. *Am J Obstet Gynecol*. 2018;
399 218(2S):S725-S737.
- 400 32. Smith KM, Lai PC, Robertson HA, Church RB, Lorscheider FL. Distribution of alpha 1-
401 fetoprotein in fetal plasma, allantoic fluid, amniotic fluid and maternal plasma of cows. *J Reprod*
402 *Fertil* 1979;57:235-8.
- 403 33. Luft AJ, Lai P, Robertson HA, Saunders NR, Lorscheider FL. Distribution of alpha-
404 fetoprotein in fetal plasma and in amniotic and allantoic fluids of the pig. *J Reprod Fertil* 1984;70:605-
405 7.
- 406 34. Hervey EJ, Slater JS. The sources of sheep foetal fluids in the later stages of gestation. *J*
407 *Physiol* 1968;194:40-1.
- 408 35. Los FJ, Hagenars AM, Marrink J, Cohen-Overbeek TE, Gaillard JL, Brandenburg H.
409 Maternal serum alpha-fetoprotein levels and fetal outcome in early second-trimester
410 oligohydramnios. *Prenat Diagn* 1992;12:285-92.

- 411 36. Ingvarsson BI, Carlsson RNK, Karlsson BW. Synthesis of α -fetoprotein, albumin and total
412 serum protein in neo-natal pigs. *Neonatology* 1978;34:259-68.
- 413 37. Lai PC, Mears GJ, van Petten GR, Hay DM, Lorscheider FL. Fetal-maternal distribution of
414 ovine alpha-fetoprotein. *Am J Physiol-Endoc M* 1978;235:E27.
- 415 38. Bader D, Riskin A, Vafsi O, Tamir A, Peskin B, Israel N, et al. Alpha-fetoprotein in the early
416 neonatal period: a large study and review of the literature. *Clin Chim Acta* 2004;349:15-23.
- 417 39. Borba LA, Nogueira CEW, Bruhn FRP, da Silva GC, Feijó LS, Canisso IF, Curcio BDR.
418 Peripheral blood markers of sepsis in foals born from mares with experimentally ascending
419 placentitis. *Vet Rec* 2020;187:29.
- 420 40. Mizejewski GJ. Alpha-Fetoprotein (AFP) and Inflammation: Is AFP an Acute and/or Chronic
421 Phase Reactant? *J Hematol Thrombo Dis* 2015;3:1-9.
- 422 41. Bartha JL, Comino-Delgado R, Arce F, Alba P, Brouillon JR, Barahona M. Relationship
423 between alpha-fetoprotein and fetal erythropoiesis. *J Reprod Med* 1999;44:689-97.
- 424 42. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference
425 distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a
426 practical, simple and clinically relevant approach in a large cohort. *J Clin Lab Anal* 1999;13:273-9.
- 427 43. Sellon DC. Disorders of the hematopoietic system. In Reed SM, Bayly WM, Sellon DC, editors.
428 *Equine Internal Medicine*; Eds.; Saunders: St Louis, Missouri, 2004.
- 429 44. Aoyagi Y, Ikenaka T, Ichida F. Alpha-fetoprotein as a carrier protein in plasma and its bilirubin-
430 binding ability. *Cancer Res* 1979;39:3571-4369.

431

432

433 **Table 1.** Mares (n= 49) assigned to three groups.

Group	Gestational length (d) (Mean ± SD)	BCS	Age	Male foals	Female foals	Breeds
1	341±10	8±1	10±5	7/20	13/20	Standardbred (n=18) Saddlebred (n=2)
2	346±12	7±1	8±5	10/15	5/15	Standardbred (n=14) Saddlebred (n=1)
3	327±12	7±1	11±5	8/14	6/14	Standardbred (n=7) Saddlebred (n=5) Quarter Horse (n=2)

434 BCS: Body Condition Score

435

436 **Table 2.** Foal complete blood cell counts at birth (median and interquartile ranges).

Parameters	Group 1	Group 2	Group 3
Hemoglobin (g/L)	152 (147-163) ^a	154 (148-160) ^a	138 (125-148) ^b
Hematocrit (L/L)	0.47 (0.45-0.49)	0.46 (0.45-0.49)	0.43 (0.41-0.48)
Erythrocytes (10 ¹² /L)	10.7 (10.3-11.9) ^a	10.8 (10.4-11.2) ^a	9.9 (9.1-10.5) ^b
Platelets (10 ⁹ /L)	196.5 (167.3-222.7)	191.0 (177.7-197.8)	196.0 (178.1-229.2)
Leucocytes (10 ⁹ /L)	7260 (6199-8255)	7700 (6962-8973)	6815 (5325-9071)
Lymphocytes (10 ⁹ /L)	1260 (1142-1437) ^a	1350 (1205-1518) ^a	1995 (1388-3005) ^b
Monocytes (10 ⁹ /L)	180 (115-256) ^a	210 (115-240) ^a	90 (64-178) ^b
Neutrophils (10 ⁹ /L)	5970 (4638-6705)	6000 (5387-7280)	4725 (2440-6354)
Eosinophils (10 ⁹ /L)	10 (0-10)	10 (10-22)	15 (10-20)
Basophils (10 ⁹ /L)	30 (30-50)	30 (30-40)	40 (19-85)

437 (a-b) Different superscript letters in row indicate differences (P < 0.05) among groups with Kruskal-
438 Wallis test.

439

440 **Table 3.** Foal blood chemistry at birth (median and interquartile ranges).

Parameters	Group 1	Group 2	Group 3
Creatine kinase (μkat/L)	3.7 (2.3-4.8)	3 (2.6-4)	4.4 (3.4-11.9)
Total bilirubin (μmol/L)	41 (32.5-47.9)	37.6 (29.1-42.7)	30.8 (23.9-49.6)
Total protein (g/L)	24 (19-28)	22 (17-25)	18 (13-29)
Albumin (g/L)	33 (30-35)	34 (31-34)	32 (27-33)
Alb/Glob (g/L)	40 (34-50)	37 (31-41)	31 (28-38)
BUN (mmol/L)	13 (11.7-14.7)	12.6 (11.1-13.9)	11.6 (9.5-15.2)
Creatinine (μmol/L)	212.2 (176.8-256.4)	238.7 (185.6-274)	265.2 (203.3-353.6)
Calcium (mmol/L)	3.3 (3.1-3.3) ^a	3.2 (3-3.4) ^a	4.3 (3.3-4.2) ^b
Magnesium (mmol/L)	0.7 (0.7-0.8)	0.8 (0.7-0.8)	0.8 (0.7-0.9)
Fibrinogen (g/L)	1.6 (1.5-1.9)	1.7 (1.4-2.7)	2.9 (1.7-4.1)

441 (a-b) Different superscript letters in row indicate significant differences (P < 0.05) among groups
442 with Kruskal-Wallis test.

Table 4. Data about mares carrying normal pregnancy and delivering healthy foals (Group 1).

ID	Days of gest. at admission	Plasma AFP at admission (µg/mL)	DBP	Gest. lenght (days)	Plasma AFP at parturition (µg/mL)	Amniotic Fluid AFP (µg/mL)
1	323	0.24	22	345	0.24	4.17
2	320	0.53	18	338	0	21.30
3	308	0.24	23	331	0.24	30.25
4	306	0.43	19	325	0.66	11.72
5	325	0.49	22	347	0.45	7.21
6	334	0.24	23	357	0.37	5.83
7	326	0.24	15	341	0.67	6.32
8	326	0.30	16	342	0.32	9.37
9	323	0.64	16	339	0.54	8.11
10	318	0.84	18	336	0.51	2.81
11	308	0.24	23	331	0.24	5.28
12	338	0.46	20	358	0.42	4.34
13	343	0.24	16	359	0.31	7.77
14	325	0.37	16	341	0.31	17.18

15	312	0.88	16	328	0.67	10.10
16	311	0.60	21	332	0.42	6.50
17	332	0.24	20	352	0.37	8.08
18	324	0.46	15	339	0.64	5.14
19	329	0.38	19	348	0.37	5.06
20	316	0.24	17	333	0.46	13.67

DBP: days before parturition (admission – foaling).

444
445

446 **Table 5:** Data about mares carrying apparently normal pregnancies and delivering sick foals (Group 2).

ID	Days of gest. at admission	Plasma AFP at admission (µg/mL)	DBP	Gest. lenght (days)	Plasma AFP at parturition (µg/mL)	Amniotic Fluid AFP (µg/mL)	Foal's weight (kg)	Placenta weight (kg)	Placenta macroscopical alterations (Y/N)	Histopathologic placenta alterations	Mare's diagnosis	Foal's diagnosis
1	320	0.26	33	353	0.57	NA	46	5.7	N	NA	/	Neonatal encephalopathy
2	320	NA	26	346	0.62	8.80	45	4.4	N	NA	/	Neonatal encephalopathy
3	327	0.48	24	351	0.93	4.60	45	5.5	N	NA	/	Neonatal encephalopathy
4	326	0.52	14	340	0.46	19.72	38	3.9	N	NA	/	Neonatal encephalopathy
5	326	1.07	9	335	0.42	16.21	42	3.8	N	NA	/	HIE
6	320	0.68	11	331	0.43	NA	39	3.1	Y	Severe hypoplasia of the chorionic villi	Placental insufficiency	Neonatal encephalopathy
7	332	0.64	16	348	0.61	9.47	50	6	N	NA	/	Neonatal encephalopathy
8	303	0.94	52	355	0.45	4.50	58	6.7	N	NA	/	Neonatal encephalopathy
9	368	0.25	3	371	0.47	5.35	40	4.1	Y	Severe hypoplasia of the chorionic villi	Placental insufficiency	Neonatal encephalopathy
10	322	0.99	14	336	0.52	8.22	43	4.2	N	NA	/	Neonatal encephalopathy
11	327	0.55	32	359	0.69	21.42	41	3.6	Y	Severe hypoplasia of the chorionic villi	Placental insufficiency	HIE

12	328	0.69	4	332	0.62	7.51	54	4.5	N	NA	/	HIE
13	335	0.24	20	355	0.31	NA	53	5.2	N	NA	/	Neonatal encephalopathy
14	332	0.42	23	355	0.38	13.67	43	5	N	NA	/	Neonatal encephalopathy
15	NA	NA	NA	329	0.61	20.45	46	7.7	Y	Severe hypoplasia of the chorionic villi and edema	Placental insufficiency	HIE

447 DBP: days before parturition (admission – foaling); HIE: Hypoxic-Ischemic Encephalopathy; NA: data not available

448

449 **Table 6.** Data about mares with high-risk pregnancy (Group 3)

ID	Days of gest. at admission	Clinical signs (N=none)	CTUP at admission (mm)	Plasma AFP at admission (µg/mL)	Cervical swab (Neg/Pos)	DBP	Gest. length (days)	Plasma AFP at parturition (µg/mL)	Amniotic fluid AFP (µg/mL)	Foal's weight (kg)	Placenta weight (kg)	Placenta macroscopical alterations (Y/N)	Histopathologic placenta alterations	Mare's Diagnosis	Foal's diagnosis
1	324	N	19	0.26	NA	13	337	0.70	NA	47	8.1	Y	Villous hypoplasia, chorionic lamina edema	Placental insufficiency	Neonatal encephalopathy
2	298	N	12	0.50	NA	22	320	0.75	13.79	41	4.5	Y	NA	Placental insufficiency	Neonatal encephalopathy
3	315	Vulvar discharge	8	0.74	Pos	25	340	0.83	NA	48	7.3	Y	Chorionic lamina edema	Placentitis/placental insufficiency	Neonatal encephalopathy
4	296	N	14	0.30	NA	39	335	0.66	25.77	48	5.8	Y	Interstitial edema and hyperemia	Placental insufficiency	HIE
5	308	Vulvar discharge, premature lactation	9	2.0	Neg	9	317	0.42	NA	37	5.1	Y	Interstitial edema and hyperemia	Placentitis/placental insufficiency	Prematurity
6	305	Premature lactation	8	0.50	Neg	9	314	0.55	11.40	23	2.3	Y	NA	Sistemic illness (laminitis)	Prematurity
7	315	N	47	0.65	Neg	15	330	NA	39.69	42	5.8	Y	Villous atrophy, microtrombosis, pigments deposition, chorionic lamina edema	Placental insufficiency	HIE
8	342	Vulvar discharge	13	NA	NA	2	344	0.40	NA	NA	NA	Y	NA	Placentitis/placental insufficiency	Sepsis
9	309	N	17	0.36	Neg	15	324	7.37	87.85	37	14.8	Y	Chorionic lamina edema and hyperemia, villous hypoplasia, microvasculitis	Placental insufficiency	Stillborn
10	342	N	7.7	NA	NA	0	342	0.63	NA	40	3.35	Y	Villous atrophy, microvasal fibrosis/hyperplasia, microtrombosis, neutrophilic infiltration	Sistemic illness (laminitis), placentitis/placental insufficiency	Dismaturity Sepsis
11	269	Vulvar discharge, premature lactation	10.3	0.52	Pos	30	299	1.51	NA	28	4.6	Y	Chorionic lamina edema, villous atrophy and necrosis	Placentitis/placental insufficiency	Stillborn

12	319	N	11	0.66	Neg	13	332	0.37	NA	43	5.5	Y	Chorionic lamina edema, villous hypoplasia	Sistemic illness (surgical colic), placental insufficiency	HIE
13	313	Vulvar discharge	9.3	NA	Pos	2	315	0.59	9.83	35	3.15	Y	Villous hypoplasia, hyperemia	Placentitis/ placental insufficiency	Prematurity
14	322	N	NA	0.24	NA	1	323	NA	32.31	NA	NA	NA	NA	Systemic illness (prepubic tendon rupture, severe abdominal ventral hernia)	Dismaturity

450

DBP: days before parturition (admission – foaling); CTUP: combined thickness of the uterus and placenta (mm); HIE: Hypoxic-Ischemic Encephalopathy; NA:

451

data not available.

452 **Table 7.** AFP concentration (ng/mL) in mares' plasma, amniotic fluid, foals' plasma at birth (0h)
 453 and after 24 and 72 h in Group 1, 2 and 3.

	Group 1	Group 2	Group 3
Mare's plasma at admission	0.38 (0.24-0.52) 0.24-0.88 n= 20	0.30 (0.24-0.41) 0.24-0.9 n= 12	0.44 (0.29-0.70) 0.24-2.00 n= 10
Mare's plasma at foaling	0.40 (0.31-0.53) (0-0.67) n= 20	0.32 (0.26-0.43) 0.24-0.61 n= 13	0.54 (0.37-0.83) 0.25-7.37 n= 11
Amniotic fluid	7.49 (5.2-11.32) ^s 2.81-30.25 n= 20	8.21 (5.35-16.5) ^s 2.76-20.5 n= 12	25.8 (9.8-38.1) [#] 10-88 n= 7
Foal's plasma at birth (0 h)	1111.4 (825.5-1476.2) ^{aS} 335.2-1996.5 n = 20	1246.3 (1038.2-1391.5) ^{aS} 865.2-2008.6 n = 13	1669.8 (1573-2808.6) ^{a#} 1331-2771 n= 11
Foal's plasma after 24 h	811.91 (598.3-1145.3) ^{bS} 246.8-1548.8 n= 20	960.7 (758.1-1294.7) ^{bS} 659.5-1669.8 n= 14	1452 (1104.7-1633.5) ^{b#} 982.5-2190.1 n= 11
Foal's plasma after 72 h	643.7 (503.7-930.5) ^{cS} 1158.5-1476.2 n = 20	718.7 (540.9-883.3) ^{cS} 97.4-1153.1 n = 11	1195.5 (929.3-1403.6) ^{c#} 689.7-2262.7 n = 11

454 Data are expressed as median (interquartile range) and min-max value.

455 Different superscript letters in columns indicate a significant difference between each time points (Mann-

456 Whitney-U-test).

457 Different superscript symbols in row indicate a significant difference among groups (Kruskal-Wallis test).

458

459

460 **Table 7.** AFP concentration (ng/mL) in mares' plasma, amniotic fluid, foals' plasma at birth (0h)
461 and after 24 and 72 h in NFM and PFM Group.

	NFM Group	PFM Group	p
Mare's plasma at admission	0.37 (0.24-0.46) 0.24-0.89 n=29	0.44 (0.32-0.72) * 0.24-2.0 n= 12	0.031
Mare's plasma at foaling	0.38 (0.31-0.47) (0.24-0.67) n= 29	0.50 (0.3-0.68) 0.24-7.37 n= 14	0.076
Amniotic fluid	7.77 (5.21-12.7) 2.76-30.25 n= 29	17.3 (9.7-31.94) * 4.49-87.85 n= 12	0.004
Foal's plasma at birth (0 h)	1150.7 (870-1409.7) 335.2-2008.6 n= 29	1657.7 (1367.3-1917.8) * 995.8-2770.9 n = 12	0.002
Foal's plasma after 24 h	819.2 (655.2-1185.8) 246.8-1669.8 n= 30	1385.5 (1074.2-1579.1) * 709.1-2190.1 n= 14	0.005
Foal's plasma after 72 h	697 (507.6-903.3) 97.41-1476.2 n = 29	1165.8 (806.8-1370.3) * 614.7-2262.7 n = 12	0.004

462 Data are expressed as median (interquartile range) and min-max value.

463 Different superscript symbols in row indicate a significant difference between two groups (Mann-Whitney-U-
464 test).

465

466

467 **Figure 1.** Placental examination of high-risk pregnancies and apparently normal
468 pregnancies delivering high risk foals. (a) Generalized edematous and heavy fetal
469 membranes (14.8 kg) with a placental/foal weight ratio of 40%. The chorioallantois had
470 2 cm thickness. (b) Chorioallantois histological preparation stained with HE showing
471 hyperemia and edema of the chorionic connective lamina associated with mild hypoplasia
472 of the chorionic villi. (c) An extensive area of transition is observed between the normal
473 (cervical star and non-gravid horn) and hypoplastic/discolored (body and gravid horn)
474 chorionic surface of the chorioallantois. (d) Histological section of the gravid horn
475 showing severe hypoplasia of the chorionic villi. (e) Grossly, an extensive focal lesion is
476 observed in the chorionic surface of the caudal pole of the chorioallantois. In detail, a
477 brown tenacious mucoid material covers the chorionic surface of the caudal pole. (f)
478 Histological section of the caudal placental pole showing necrosis of the chorionic villi,
479 mild fibrosis and edema of the connective lamina.

